Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.

Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC

Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease. 

Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups 

Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia. 

Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML 

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients. 

Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC 

News

FDA News

Latest News

Oncology Drug Crash Course

Media

Insights

Medical World News

Peer Exchange

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Cancer Insight Summary Slides

Continuing Education

Resources

Contributors

MPN Symptom Management

Webinars

Subscribe

Partners

Articles

In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months. 

Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports

Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer
Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.

Oncology Drug Crash Course: Elacestrant (Orserdu)

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Meredith Donahue, APRN-BC, discusses emerging therapies in metastatic prostate cancer. 

Genetic Testing Is Becoming an Important Conversation in Metastatic Prostate Cancer

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Quality Improvement

1rem

Authors

At the 3rd annual School of Nursing Oncology (SONO) meeting, we got the chance to sit down with Madelaine Kuiper RN, MSN, and talk about what adverse events come with immune therapy for patients with breast cancer. 

Explaining Adverse Events of Immune Therapy to Patients with Breast Cancer

Madelaine Kuiper RN, MSN

Articles

Latest Conference Coverage